NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines

GGC Formulary
- 1 Gastro-intestinal system
- 2 Cardiovascular system
- 3 Respiratory system
- 4 Central nervous system
- 5 Infections
- 6 Endocrine system
- 7 Obstetrics, gynaecology and urinary-tract disorders
- 8 Malignant disease and immunosuppression
- 9 Nutrition and blood
- 10 Musculoskeletal and joint diseases
- 11 Eye
- 12 Ear, nose and oropharynx
- 13 Skin
- 14 Immunological products and vaccines
  - 14.4 Vaccines and antisera
  - 14.5 Immunoglobulins
- 15 Anaesthesia
  - 15.1 General anaesthesia
  - 15.2 Local anaesthesia
- 16 Treatment of poisoning
  - 16.1 Removal and elimination
  - 16.2 Specific antidotes
Latest Formulary Decisions
Medicines Update Blogs
Clinical Guidelines
Adult Therapeutics Handbook
Medicines Policies
Other Formularies
PACS, IPTR and ULM
Patient Information
Prescribing Resources
Shared Care Agreements
Supply Problems (StaffNet)
Contact Us

Go Home

Subscribe to Medicines Update via

Email Subscription

Latest Medicines Update Posts

Archives

Tags

Medicines Update

Sacubitril / valsartan

Heart MCN Key Message

All new initiations of sacubitril/valsartan must be discussed on an individual patient basis with a consultant with special interest in heart failure. For safety reasons, every patient commenced on sacubitril/valsartan should be under the care of the Heart Failure Liaison Nurses through-out the initiation and up-titration phase.

NHSGGC guidelines on Sacubitril/Valsartan are available on Staffnet

Published 25/4/17